Press release
Steady Expansion Forecast for Kidney Cancer Drugs Market, Projected to Reach $10.31 Billion by 2029
Kidney Cancer Drugs Market
Kidney Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the kidney cancer drugs market has witnessed a consistent growth. The market size, which is currently valued at $8.22 billion as of 2024, is projected to expand to $8.53 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.8%. The market's growth during the historical period can be attributed to factors such as increased spending on healthcare, fast-paced growth of the elderly population, a rise in pharmaceutical research and development spending, and advancements in the discovery of cancer drugs.
Kidney Cancer Drugs Market Size Forecast: What's the Projected Valuation by 2029?
The market for kidney cancer drugs is anticipated to witness consistent expansion in the coming years, hitting a valuation of "$10.31 billion in 2029 with a compound annual growth rate (CAGR) of 4.8%. Factors like the growing elderly population, escalating health care spending, increasing mergers and collaborations for drug innovation, and the untapped potential of emerging markets underpin the projected growth in the forecast period. Noteworthy trends for the same period encompass the utilization of 3D technology in drug manufacturing and model creation, investment in biomarkers, the introduction or adoption of novel treatment methods, enhancement of treatments through personalized medicine, capitalization on AI solutions, and strategic collaborations with other corporations or government entities to expedite the production of new drugs.
View the full report here:
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report
What Are the Drivers Transforming the Kidney Cancer Drugs Market?
The escalation in kidney cancer occurrence serves as a major propellant for the kidney cancer medication market. Lifestyle changes, tobacco use, and unhealthy eating habits are among the contributing factors to the proliferation of kidney cancer cells. As indicated by the American Cancer Society in January 2022, a health organization based in the US whose objective is to eradicate cancer, there is an anticipation of 79,000 newly diagnosed kidney cancer cases in the year out of which, 50,290 will be men and 28,710 women, with 13,920 individuals succumbing to the illness, including 8,960 men and 4,960 women. The diagnosis tends to mostly happen between the ages of 65 and 74, the average diagnosis occurs at the age of 64. The incidence of kidney cancer is quite rare for individuals under the age of 45. This scenario fuels the expansion of the kidney cancer medication market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp
What Long-Term Trends Will Define the Future of the Kidney Cancer Drugs Market?
Leading businesses in the kidney cancer drugs market are concentrating on advancements like biosimilar development to improve treatment methods, enhance patient affordability, and speed up innovation in cancer care. Biosimilar development involves producing biological medicines that closely resemble an already authorized reference product, guaranteeing similar effectiveness, safety, and quality. For example, in November 2022, Amneal Pharmaceuticals Inc., a pharmaceutical company based in the United States, introduced RELEUKO (filgrastim-ayow). This is a biosimilar to Neupogen (filgrastim), also developed by Amneal Pharmaceuticals, and is formulated to manage neutropenia, especially in chemotherapy patients.
Which Segments in the Kidney Cancer Drugs Market Offer the Most Profit Potential?
The kidney cancer drugs market covered in this report is segmented -
1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users
Subsegments:
1) By Renal Cell Carcinoma (RCC): Targeted Therapies, Immune Checkpoint Inhibitors, Cytokine Therapies
2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents, Immunotherapy Agents, Antibody-Drug Conjugates (ADCs)
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2591&type=smp
Which Firms Dominate the Kidney Cancer Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the kidney cancer drugs market include Pfizer Inc., Novartis AG, ExelixisInc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Amgen Inc ., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Teva Pharmaceutical Industries Ltd., Kitov Pharma Limited, CureTech Ltd., Neopharma
Which Regions Offer the Highest Growth Potential in the Kidney Cancer Drugs Market?
North America was the largest region in the kidney cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2591
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Steady Expansion Forecast for Kidney Cancer Drugs Market, Projected to Reach $10.31 Billion by 2029 here
News-ID: 4182679 • Views: …
More Releases from The Business Research Company
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Key Trends Influencing the Growth of the Gynecology Drugs Market in 2025: Launch …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Gynecology Drugs Market Through 2025?
In recent times, there has been a consistent increase in the size of the gynecology drugs market. It is projected to expand from a value of $43.27 billion in 2024 to $45.06 billion in 2025, with a…
Surging Demand Drives Growth In The Fetal Bovine Serum Market: Strengthening the …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Fetal Bovine Serum Market Through 2025?
The market size of fetal bovine serum has seen consistent growth in the past few years. The projected growth is from $1.02 billion in 2024 to $1.06 billion in 2025, with a compound annual growth rate…
Healthcare Expenditure Surge Boosts Drug Discovery Market Emerges as a Core Driv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Drug Discovery Market Through 2025?
The market size of drug discovery has significantly expanded in the past few years. Projections indicate that it will escalate from $110.26 billion in 2024 to $124.11 billion in 2025, experiencing a compound annual growth rate (CAGR)…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
